Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Down 5.8% in September

Esperion Therapeutics, Inc. (NASDAQ:ESPR) saw a large decline in short interest in the month of September. As of September 15th, there was short interest totalling 38,090,000 shares, a decline of 5.8% from the August 31st total of 40,440,000 shares. Based on an average daily trading volume, of 5,490,000 shares, the days-to-cover ratio is currently 6.9 days. Currently, 19.6% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ESPR. Needham & Company LLC cut their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Bank of America downgraded shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and cut their price target for the stock from $2.90 to $2.50 in a research note on Thursday, June 20th. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday. Finally, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to MarketBeat, Esperion Therapeutics currently has an average rating of “Hold” and an average price target of $8.17.

Esperion Therapeutics Stock Up 0.3 %

Shares of Esperion Therapeutics stock traded up $0.01 during trading hours on Monday, hitting $1.69. The company’s stock had a trading volume of 784,933 shares, compared to its average volume of 6,508,288. The business has a fifty day moving average of $1.90 and a 200 day moving average of $2.20. Esperion Therapeutics has a 1-year low of $0.70 and a 1-year high of $3.40. The company has a market capitalization of $319.24 million, a PE ratio of -1.72 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.10. The company had revenue of $73.83 million during the quarter, compared to analyst estimates of $51.90 million. On average, sell-side analysts anticipate that Esperion Therapeutics will post -0.04 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Esperion Therapeutics

Hedge funds have recently modified their holdings of the stock. BOKF NA purchased a new position in Esperion Therapeutics in the 2nd quarter worth approximately $26,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics in the second quarter valued at $28,000. CVI Holdings LLC acquired a new stake in Esperion Therapeutics during the 1st quarter valued at $37,000. State Board of Administration of Florida Retirement System purchased a new stake in Esperion Therapeutics during the 1st quarter worth $50,000. Finally, National Bank of Canada FI increased its stake in Esperion Therapeutics by 115.9% during the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 10,225 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.